Option 4 Sample Clauses
Option 4. Any warning authorized by any Proposition 65 law or regulation effective on or after the Effective Date.
Option 4. If Sublessees are to have non-disturbance rights, then use one of the following options: Option 4A – Use if sublease consent is NOT required:
Option 4. Employees may choose to enroll in a qualified prepaid health maintenance organization (HMO) plan offered by Xxxxxx Permanente that provides comprehensive medical care through a network of participating hospitals, physicians and other health care providers. The employee price tag will be 10% through December 31, 2012 according to the schedule in Appendix B-1; 11% as of January 1, 2013 according to the schedule in Appendix B-2; 12% as of January 1, 2014; 13% as of January 1, 2015; 14% as of January 1, 2016; and 15% as of January 1, 2017. A prescription drug benefit is included with the HMO offered. The co-pay structure through December 31, 2017 shall be as follows: up to 60-day supply - $5 generic; $5 brand; at participating community pharmacy - $15 generic; $15 brand; Mail Order - 90-day supply - $5 generic; $5 brand.
Option 4. If Option 4 was chosen in the Subleases section, then use the following: [SUBLESSOR’S NAME] [OPTIONAL: If the Sublessor is a corporation, limited partnership, society, utility or municipality, then type a comma after the Sublessor’s Name and include the statute under which the entity received [SUBLESSEE’S NAME] [OPTIONAL: If the Sublessee is a corporation, limited partnership, society, utility or municipality, then type a comma after the
Option 4. Upon negotiation an employee may work the nominated RDO and receive payment at the appropriate rate for it within the same work cycle.
Option 4. In the event that during Stage 1 or Stage 2, a compound has been identified as an MCP-1 Inhibitor and such compound also has activity as an inhibitor for a chemokine other than MCP-1, and Warner notifies Leukosite in writing that Warner desires to optimize that non-MCP-1 activity instead of MCP-1 under Option 2 the parties shall proceed under Option 2 (with appropriate expansion to the definitions of "Field", Background Technology, Collaboration Technology and similar terms hereof) with respect to such compound for such activity unless within thirty (30) days thereafter LeukoSite elects in writing not to proceed under Option 2. If LeukoSite elects in writing not to continue with collaborative research with respect thereto (or is prevented from continuing such collaborative research with respect thereto because of conflicting third party obligations), in such event, such compound shall become a Warner Product subject to the terms and conditions of this Agreement, except that no license is granted by LeukoSite under Section 5.1 to such Warner Product to the extent that LeukoSite is prohibited from granting licenses under its Patent Rights which are not Background Technology with respect to such Warner Product as an inhibitor of a chemokine other than MCP-1 by an agreement with a third party. As a result of such compound becoming a Warner Product under this Option 4 upon the later of (i) January 2, 1996 or (ii) two weeks after LeukoSite elects in writing not to continue such collaborative research Warner will purchase $1 Million of LeukoSite capital stock (Preferred if at the time of purchase the IPO has not been completed, and common if the IPO has been completed by such time), upon terms substantially similar to those of the Preferred Stock Purchase Agreement dated the date of this Agreement, at (i) $3.00 per share if at the time of purchase LeukoSite has not yet completed its IPO or (ii) 125% of the Market Price for LeukoSite's Common Stock at the time of purchase if at such time of purchase LeukoSite has completed its IPO. In the event that any such sale and purchase shall be of shares of Preferred Stock of LeukoSite, the terms of such shares of Preferred Stock shall be identical to the terms of LeukoSite's Series C Convertible Preferred Stock, except that (i) such shares of Preferred Stock shall be from a separate, newly-created series of Preferred Stock and (ii) unless otherwise agreed to by the parties, the liquidation preference of such shares of Pref...
Option 4. In lieu of time, if a staff member and the principal agree, per session can be paid. In such circumstances, the work must be done outside of school hours and appropriate payroll procedures must be followed.
Option 4. This is a Bespoke service for Clients who require a highly personal level of Service, to include an individually tailored Portfolio. This service level provides access to Collective Investment Schemes including Authorised Unit Trusts, Investment Trusts, Exchange Traded Funds and Structured Investment Products. Bespoke Clients receive our global ‘Outlook’ quarterly by email and We will meet with You biannually or more frequently, up to four times a year. You may contact Us at any time by email, telephone or in person to discuss your Portfolio. Initial Charge : Up to 3% Annual Charge : 1.25% For example – under Option 4 an investment of £500,000 will incur an initial charge of £6,250 at 1.25%. The minimum charge is £5,000 and an annual charge to review of £6,250 at 1.25%. The amount You pay each year will fluctuate with the value of Your investment. If this increases in value our annual charge will also increase.
Option 4. Any warning authorized by any Proposition 65 law or regulation effective on or after the Effective Date. Respecting the warnings defined in Sections 3.2.1, 3.2.2, and 3.3.3, the warning must be in a type size no smaller than the largest type size used for other consumer information on the product. In no case shall the warning appear in a type size smaller than 6-point type.
Option 4. An employee may choose to use any combination of Options #1, #2, and/or #3 during the period in which Workers’ Compensation is being received.